Issue 76 of the journal Cuadernos DF (Pharmaceutical Law Review) now available
Interruption of supply or the withdrawal of medicines from the market and competition rules. Henar González Durántez y Pilar Carrasco del Olmo 2021 versión of Pharmaceutical Industry Code of Best Practices. Teresa Paz-Ares Rodríguez, Beatriz Cocina Arrieta y Nuria Porxas Roig Regulatory framework aplicable to observational studies with medicines for human use foreseen […]
The withdrawal or interruption of medicine supply from a competition law perspective
Recent investigations of the pharmaceutical sector by the competition authorities demonstrate a focus on examining a number of actions that could entail an interruption of supply or even the withdrawal of medicinal products from the market by pharmaceutical companies. Specifically, in the field of pharmaceutical law, the competition authorities have devoted particular attention to two […]
Vaccines in times of pandemic
On 19 January CEFI organised a seminar to deepen our understanding of vaccines in times of pandemic. Interest in the debate, reflected in the number of registrations (298) and the quality of the speakers, most of whom are at the forefront of work to provide a vaccine for the current health crisis, ensured the session […]
Vaccine debate at CEFI
Fascinating debate on vaccines with 266 registered participants and fantastic presentations by the speakers.
Final days for registration: Online conference ‘Deepening our understanding of vaccines in times of pandemic’
On 19 January 2021, CEFI will hold the online conference entitled Deepening our understanding of vaccines in times of pandemic. Registration is free of charge. Programme and registration
Two new issues of CEFI’s journal published
Two new issues of the journal published by CEFI are available: Cuadernos de Derecho Farmacéutico issue 75 (October-December 2020). Comunicaciones en Propiedad Industrial y Derecho de la Competencia issue 91 (September-December 2020).
CEFI contributes to the debate on vaccines in times of pandemic
On 19 January 2021, CEFI will hold an online conference entitled Deepening our understanding of vaccines in times of pandemic. Programme and registration
Eventful days of regulation and legislation in the world of pharma and innovation
There have been some eventful days recently in terms of important pharmaceutical regulations and legislation: Community pharma strategy to which we dedicated a post on LinkedIn Proposal for a Data Governance Regulation. Re-use of certain public sector data, including health data, which is key to boosting biomedical research. RD on observational studies. Simplifying administrative procedures, […]
Global regulatory alignment on COVID-19 medicines and vaccines
Global action in the fight against the COVID-19 pandemic. Joint statement by the International Coalition of Medicines Regulatory Authorities (ICMRA) and the World Health Organization (WHO), supported by the Spanish Medicines and Health Products Agency (AEMPS), with regulatory agencies adopting a series of measures to promote alignment on regulatory processes across all countries. Global collaboration, […]
Expert analysis on data protection
In the next issue of the Comunicaciones journal, CEFI is pleased to count on the expert opinion of Jesús Rubí Navarrete, Deputy Director of the Spanish Data Protection Agency (AEPD) and Rafael Garcia Gozalo, Executive Advisor and Head of the AEPD’s International Division, as they analyse the Guideline on the use of cookies in light […]
Improving access to therapeutic innovation
Natividad Calvente Cestafe, Director of Innovation, Training and Institutional Relations at the General Council of Pharmaceutical Associations contributes to a monographic issue of the journal Cuadernos de Derecho Farmacéutico [Pharmaceutical Law Review] with a magnificent article on early access to therapeutic innovation, which is one of the greatest challenges faced by health systems and the […]
La Fundación CEFI presenta sus alegaciones al Proyecto de Orden de precios de referencia 2020
El sistema de precios de referencia y las sucesivas ordenes anuales de precios de referencia pretenden contribuir a la sostenibilidad del SNS. También deben fomentar el justo equilibrio entre innovador-genérico/biosimilar, la competencia y la competitividad en el mercado farmacéutico y sanitario. Las decisiones en materia de precios deben responder a una situación real de mercado, […]
